What is the efficacy and safety of ramucirumab in the treatment of gastric cancer?

Ramucirumab is a humanized monoclonal antibody that specifically blocks vascular endothelial growth factor receptor 2 (VEGFR2) and downstream angiogenesis-related pathways. Approved for use in patients with unresectable disease, or those who have progressed after a platinum-containing or fluorouracil-containing regimen. At present, the drug has been introduced in Hong Kong, and the specific process cost can be evaluated in the early stage of Hong Kong and safety health.

The application for ramucirumab for this indication is based on a global, randomized, double-blind, phase III clinical study (REGARD) trial in 355 patients with advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma. The investigators divided the patients into a 2:1 ratio, with 238 patients assigned to ramucirumab and another 117 to placebo controls.

The primary endpoint is overall survival. The results of the study demonstrated that patients in the ** group had a longer median OS (months versus months) and a longer median PFS.

Ramucirumab was approved by the FDA on April 21, 2014 for the treatment of **gastric cancer or gastroesophageal junction adenocarcinoma, metastatic non-small cell lung cancer and colorectal cancer. It is recommended to see an oncologist first, and the doctor will make a judgment and guide on the medication.

Ramucirumab is a vascular endothelial growth factor receptor 2 antagonist. It specifically binds to VEGF receptor 2 and blocks the coordination of VEGF ligands, VEGF-A, VEGF-C, and VEGF-D. Thus, ramucirumab can inhibit ligand-excited activation of VEGF receptor 2, thereby inhibiting ligand-induced proliferation as well as migration of human endothelial cells.

In animal experiments, ramucirumab inhibited angiogenesis. At present, the drug has been introduced in Hong Kong, and the specific process cost can be evaluated in the early stage of Hong Kong and safety health.

This is not yet available in China, so it is still not available in major hospitals and pharmacies.

If you need it urgently, you can go to (Centakang Pharmaceutical Medical) and you should be able to buy it.

Yes, the Internet is very convenient now, just find a reliable platform.

I just bought it through Hong Kong Jimin Pharmaceutical not long ago, and I am quite satisfied with the service. The stock is stable and sufficient, and the delivery speed is fast, after all, human life is at stake, and you can't wait. Satisfied with my answer? If you are satisfied, please adopt it.

Overall survival in patients with advanced gastric or GEJ adenocarcinoma who received paclitaxel + ramucirumab versus paclitaxel as a second-line ** after failure of platinum and fluorouracil combinations** (with or without anthracyclines [epirubicin or doxorubicin]).

1. Experimental theme.

A phase III randomized, double-blind, multicenter study of ramucirumab + paclitaxel versus paclitaxel in patients with advanced gastric or GEJ adenocarcinoma in the second line** (after failure of platinum and fluorouracil in combination** with or without anthracyclines [epirubicin or doxorubicin]).

2. Indications.

Adenocarcinoma of the stomach or gastroesophageal junction.

Third, the purpose of the test.

To investigate overall survival in patients with advanced gastric or GEJ adenocarcinoma with ramucirumab + paclitaxel versus paclitaxel as a second-line (after failure of platinum and fluorouracil in combination** with or without anthracyclines [epirubicin or doxorubicin]).

5.Inoperable or metastatic disease, prior first-line regimen of platinum-containing drugs in combination with fluorouracil** (platinum-based agents include cisplatin, carboplatin, or oxaliplatin; Fluorouracil includes 5-FU, capecitabine, or S-1) with or without an anthracycline (epirubicin or doxorubicin). The patient has documented clear radiographic or symptomatic disease progression (eg, any new or malignant pleural effusion on ultrasound) during the first-line** period or within 4 months of the last dose, and the diagnosis can be confirmed by pathologic diagnostic criteria (histology or cytology) when appropriate.

6. Exclusion Criteria.

1.Have squamous cell carcinoma or undifferentiated gastric cancer;

2.Has received any first-line chemotherapy other than platinum and fluorouracil with or without anthracyclines**Advanced gastric or GEJ adenocarcinoma;

3.Prior receipt of the following systemic chemotherapy: epirubicin cumulative dose (900 mg m2) or doxorubicin (400 mg m2);

4.Prior receipt of any systemic ** targeting VEGF or VEGFR signaling pathways. Prior receipt of other types of targeting** is permitted, but it is required to be discontinued at least 28 days prior to randomization**;

5.Being receiving anticoagulation with warfarin, low molecular weight heparin, or equivalent**. Patients receiving prophylactic low-dose anticoagulation** may be eligible to participate in the study, but only if the anticoagulation parameters specified in the inclusion criteria (INR;

6.Ongoing treatment with non-steroidal anti-inflammatory drugs or other antiplatelet agents**. However, aspirin (acetylsalicylic acid) at a dose of 325 mg a day or less is allowed;

7.Have symptomatic congestive heart failure or have symptomatic or poorly controlled arrhythmias;

8.Has intestinal obstruction, has or has a history of the following: inflammatory bowel disease or extensive bowel resection, Crohn's disease, ulcerative colitis, or chronic diarrhea.

Rademolumab is a humanized IgG-1 monoclonal antibody with high affinity for VEGFR-2 that blocks VEGF activation. CYR is a drug used in patients whose cancer is not resectable (unresectable) and in which the tumor has spread and metastasized after fluoropyrimidine or platinum. My friend was diagnosed with stomach cancer and needed ramucirumab.

There are no hospitals in the mainland, and they went to Xianggang through Hong Kong Adventist Health Doctor to use the drug.

Ramucirumab cyramza is indicated for patients with unresectable cancer (unresectable) and for patients with gastric cancer whose tumors have spread ** after fluoropyrimidine or platinum drugs**, and has been shown to prolong the survival of patients with advanced gastric cancer and liver cancer. If patients want to buy the drug, they can consult Adventist Health.

Hong Kong's drug introduction system is very efficient, and the drug introduction is synchronized with the world, and ramulusab is available. Ramucirumab is a humanized monoclonal targeted antibody that specifically blocks vascular endothelial growth factor receptor 2 (VEGFR2) and downstream angiogenesis-related pathways. According to Hong Kong Health, Ramucirumab has statistically significant OS and PFS benefits compared with placebo in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed after ramucirumab first-line **, and the safety is acceptable.

Hello, this is not currently listed in Chinese mainland, if you need to buy it, you can only go to Hong Kong.

If you feel troublesome, then you can practice directly (Shengtaihe Pharmaceutical Medical) and buy it.

Ramucirumab, domestic wood has!

Hello, it is not on the market yet, and stomach cancer is generally surgery.

That is, ask someone else to buy it for you, or just ask those who specialize in buying medicine to buy it.

At the same time, you can also try it here (Centakang Pharmaceutical).

Regardless of whether there is surgery or chemotherapy for gastric cancer, medicine (traditional Chinese medicine) should be taken and traditional Chinese and Western medicine should be combined. This one is certain (it can be operated on in the early stage, but it is not helpful in the late stage).

Usually we always say "integration of traditional Chinese and Western medicine", when encountering this kind of serious disease, it is really the time to integrate traditional Chinese and Western medicine, should be comprehensive, not just one method.

Moreover, cancer is a lifelong disease (when the cancer cells have not spread, they can be removed, but even if they are cut cleanly, there are always cancer cells in the body, and with the accumulation of time, the ** rate is high), we must insist on taking medicine, and we must not think that everything will be fine after surgery and chemotherapy (after surgery and chemotherapy, there is still a long way to go, and the main task at this time is to prevent **). It's medical common sense. Many patients think that they have been cured after surgery and the doctor clearly says that "the operation was successful".

This is obviously a lack of medical knowledge, and as a result, it suffers from this loss). You should take the medicine after the operation, and if you don't stop taking the medicine, you can not **, thank God it is already a great achievement. Not to mention not taking medicine.

Chinese medicine can be fully considered. It is treated with traditional Chinese medicine pills for dissolving stasis and dispersing knots, detoxifying and reducing swelling, and for pimples and tumors. If you find the right medicine, the effect will be enhanced.

The author is well aware of the charm of traditional Chinese medicine, and has witnessed a large number of typical cases of malignant tumors being treated by traditional Chinese medicine, which verifies the uniqueness of traditional Chinese medicine in the motherland. In particular, it has a special effect on diseases in the digestive tract from top to bottom that can be directly in contact with medicine, such as esophageal cancer, colon cancer, stomach cancer, rectal cancer, and lymphoma. If you have undergone surgery or chemotherapy, one of the obvious effects of traditional Chinese medicine is that all kinds of uncomfortable symptoms of the patient will be significantly reduced and improved in the short term.